fluoxetine has been researched along with Diabetes Mellitus, Type 1 in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans." | 9.13 | Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. ( Briscoe, VJ; Davis, SN; Ertl, AC; Tate, DB, 2008) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 9.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 7.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "Previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans." | 5.13 | Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. ( Briscoe, VJ; Davis, SN; Ertl, AC; Tate, DB, 2008) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 5.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 3.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "Fluoxetine treatment significantly reduced the BW gain, hyperglycaemia, creatinine, and BUN in diabetic rats." | 1.72 | Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes. ( Alarcón-Torrecillas, C; Fernández-González, JF; García-Domingo, M; García-Pedraza, JÁ; López, C; Martín, ML; Morán, A; Rodríguez-Barbero, A, 2022) |
| " Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination." | 1.56 | A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. ( Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Pedraza, JÁ | 1 |
| Fernández-González, JF | 1 |
| López, C | 1 |
| Martín, ML | 1 |
| Alarcón-Torrecillas, C | 1 |
| Rodríguez-Barbero, A | 1 |
| Morán, A | 1 |
| García-Domingo, M | 1 |
| Sioofy-Khojine, AB | 1 |
| Honkimaa, A | 1 |
| Hyöty, H | 1 |
| Briscoe, VJ | 1 |
| Ertl, AC | 1 |
| Tate, DB | 1 |
| Davis, SN | 1 |
| Bech, P | 1 |
| Raabaek Olsen, L | 1 |
| Jarløv, N | 1 |
| Hammer, M | 1 |
| Schütze, T | 1 |
| Breum, L | 1 |
| Sawka, AM | 1 |
| Burgart, V | 1 |
| Zimmerman, D | 1 |
| Lustman, PJ | 1 |
| Freedland, KE | 1 |
| Griffith, LS | 1 |
| Clouse, RE | 1 |
| Lear, J | 1 |
| Burden, AC | 1 |
| Ramirez, LC | 1 |
| Rosenstock, J | 1 |
| Strowig, S | 1 |
| Cercone, S | 1 |
| Raskin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6[NCT00592670] | 48 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Program ACTIVE: Implementing a Cognitive Behavioral Therapy and Physical Activity Program for Black Men With Comorbid Diabetes and Depression[NCT04369001] | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to Due to covid-19 and social distancing, this study was terminated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluoxetine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Fluoxetine; Homeostasis; Humans; Hypo | 2008 |
Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, | 2000 |
6 other studies available for fluoxetine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.
Topics: Administration, Oral; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2022 |
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabe | 2020 |
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major | 1999 |
Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride.
Topics: Adolescent; Awareness; Depression; Diabetes Mellitus, Type 1; Fluoxetine; Humans; Hypoglycemia; Male | 2000 |
Fluoxetine side-effects mimicking hypoglycaemia.
Topics: Adult; Diabetes Mellitus, Type 1; Diagnosis, Differential; Female; Fluoxetine; Humans; Hypoglycemia | 1992 |
Effective treatment of bulimia with fluoxetine, a serotonin reuptake inhibitor, in a patient with type I diabetes mellitus.
Topics: Adult; Bulimia; Diabetes Mellitus, Type 1; Female; Fluoxetine; Humans; Neurotransmitter Uptake Inhib | 1990 |